CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Geometry as a Confounder When Assessing Ventricular Systolic Function: Comparison Between Ejection Fraction and Strain Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity Association Between Living in Food Deserts and Cardiovascular Risk

Review Article2017 Oct 24;70(17):2186-2200.

JOURNAL:J Am Coll Cardiol. Article Link

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

Lewis GA, Schelbert EB, Miller CA et al. Keywords: diastolic dysfunction; ejection fraction; heart failure; heart failure with preserved ejection fraction; myocardial fibrosis; titin

ABSTRACT

Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and which have potentially confounded previous HFpEF trials. A greater understanding of the in vivo human processes involved, and in particular, which are the causes and which are the downstream effects, may allow the syndrome of HFpEF to be distilled into distinct diagnoses based on the underlying biology. From this, specific interventions can follow, targeting individuals identified on the basis of their biological phenotype. This review describes the biological phenotypes of HFpEF and therapeutic interventions aimed at targeting these phenotypes.